CHU ST-E
Abstract:Purpose: In Spiral Magnetic Resonance Spectroscopic Imaging (MRSI), achieving suitable spatio-temporal resolutions requires interleaving. Sampling inconsistencies occurring between temporally interleaved signals, -whether due to time-interleaved ADCs or phase/frequency mismatches in the excitation and demodulation stages-, result in artifacts in the recombined data. This paper proposes a mathematical description of these unavoidable artifacts and a postprocessing solution to circumvent the issues and mitigate them. Methods: The study proposed a detailed description and explanation of these artifacts using data acquired with MRSI interleaved sequence with gradients off, as well as standard interleaved FID sequence. The random signal mismatch between the interleaves was described as additional artifactual signals $ψ$(t) at each temporal interleave. A model was further proposed to match the acquired signal in relation to the ideal, artifact-free signal. Considering M interleaves, a correction method was derived relying on estimating 4 parameters in the $ψ$(t) model for each interleave by minimizing a multivariable cost function. This correction method was evaluated on spectra acquired from phantoms and in vivo acquisitions obtained in healthy volunteers. Results: The proposed correction method significantly reduced artifacts by a factor of 4 in the phantom and 1.8 in the healthy volunteers. This correction ensured accurate spectral quantification in regions where artifacts overlapped with the content of interest, such as lipids in subcutaneous fat. Additionally, it was demonstrated that appropriately selecting the number of temporal interleaves can shift the artifact away from the frequency of interest, leveraging the periodic and limited frequency span of the observed artifacts. Conclusion: In spiral-MRSI, temporal interleaves, while enhancing spectral bandwidth, introduced spurious content characterized by distinctive resonance frequencies and nonreproducible amplitudes and phases. The study proposes two solutions: manipulating the number of interleaves to control artifact frequency localization or using a retrospective correction method to approximate and attenuate artifacts.
Abstract:Background: Implementing a standardized 31P-MRS dynamic acquisition protocol to evaluate skeletal muscle energy metabolism and monitor muscle fatigability1,2, while being compatible with various longitudinal clinical studies on diversified patient cohorts, requires a high level of technicality and expertise. Furthermore, processing data to obtain reliable results also demands a great degree of expertise from the operator. In this two-part article, we present an advanced quality control approach for data acquired using a dynamic 31P-MRS protocol. The aim is to provide decision support to the operator in order to assist in data processing and obtain reliable results based on objective criteria. We present first in part one, an advanced data quality control (QC) approach of a dynamic 31P-MRS protocol. Part two is an impact study demonstrating the added value of the QC approach to explore clinical results derived from two patient populations with significant fatigue: COVID19 and multiple sclerosis (MS). Experimental: 31P-MRS was performed on a 3T clinical MRI in 175 subjects from clinical and healthy control populations conducted in a University Hospital. An advanced data QC Score (QCS) was developed using multiple objective criteria. The criteria were based on current recommendations from the literature enriched by new proposals based on clinical experience. The QCS was designed to indicate valid and corrupt data and guide necessary objective data editing to extract as much valid physiological data as possible. Dynamic acquisitions using an MR-compatible ergometer ran over a rest(40s), exercise(2min), and a recovery phase(6min). Results: Using QCS enabled rapid identification of subjects with data anomalies allowing the user to correct the data series or reject them partially or entirely as well as identify fully valid datasets. Overall, the use of the QCS resulted in the automatic classification of 45% of the subjects including 58 participants that had data with no criterion violation and 21 participants with violations that resulted in the rejection of all dynamic data. The remaining datasets were inspected manually with guidance allowing acceptance of full datasets from an additional 80 participants and recovery phase data from an additional 16 subjects. Overall, more anomalies occurred with patient data (35% of datasets) compared to healthy controls (15% of datasets). Conclusion: This paper describes typical difficulties encountered during the dynamic acquisition of 31P-MRS. Based on these observations, a standardized data quality control pipeline was created and implemented in both healthy and patient populations. The QC scoring ensures a standardized data rejection procedure and rigorous objective analysis of dynamic 31P-MRS data obtained from patients. The contribution of this methodology contributes to efforts made to standardize the practices of the 31P-MRS that has been underway for a decade, with the ultimate goal of making it an empowered tool for clinical research.
Abstract:Background: In this second part of a two-part paper, we intend to demonstrate the impact of the previously proposed advanced quality control pipeline. To understand its benefit and challenge the proposed methodology in a real scenario, we chose to compare the outcome when applying it to the analysis of two patient populations with a significant but highly different types of fatigue: COVID19 and multiple sclerosis (MS). Experimental: 31P-MRS was performed on a 3T clinical MRI, in 19 COVID19 patients, 38 MS patients, and 40 matched healthy controls. Dynamic acquisitions using an MR-compatible ergometer ran over a rest(40s), exercise(2min), and a recovery phase(6min). Long and short TR acquisitions were also made at rest for T1 correction. The advanced data quality control pipeline presented in part 1 is applied to the selected patient cohorts to investigate its impact on clinical outcomes. We first used power and sample size analysis to estimate objectively the impact of adding QCS. Then, comparisons between patients and healthy control groups using validated QCS were performed using unpaired T-tests or Mann-Whitney tests (p<0.05).Results: The application of the QCS resulted in increased statistical power, changed the values of several outcome measures, and reduced variability (SD). A significant difference was found between the T1PCr and T1Pi of MS patients and healthy controls. Furthermore, the use of a fixed correction factor led to systematically higher estimated concentrations of PCr and Pi than when using individually corrected factors. We observed significant differences between the two patient populations and healthy controls for resting [PCr] -- MS only, [Pi], [ADP], [H2PO4-] and pH -- COVID19 only, and post-exercise [PCr],[Pi] and [H2PO4-] - MS only. The dynamic indicators $\tau$PCr, $\tau$Pi, ViPCr and Vmax were reduced for COVID19 and MS patients compared to controls. Conclusion: Our results show that QCS in dynamic 31P-MRS studies results in smaller data variability and therefore impacts study sample size and power. Although QCS resulted in discarded data and therefore reduced the acceptable data and subject numbers, this rigorous and unbiased approach allowed for proper assessment of muscle metabolites and metabolism in patient populations. The outcomes include an increased metabolite T1, which directly affect the T1 correction factor applied to the amplitudes of the metabolite, and a prolonged $\tau$PCr indicating reduced muscle oxidative capacity for patients with MS and COVID19.
Abstract:This work presents a fast and simple method based on spiral MRSI for mapping the IMCL and EMCL apparent content, which is a challenging task and it compares this indicator to classical quantification results in muscles of interest.